CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 218 enrolled
Drug / intervention
Docetaxel +7 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03137771
NCT03137771Phase 2Active

Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

NRG Oncology·interventional·Posted May 3, 2017·Updated Jun 8, 2026

In Brief

A Phase 2 clinical trial evaluating 3-Dimensional Conformal Radiation Therapy (3D-CRT), Docetaxel, and 6 other interventions for Recurrent Non-Small Cell Lung Carcinoma and Stage IV Non-Small Cell Lung Cancer. Active but no longer recruiting, targeting 218 participants across 301 sites in 4 countries.

Detailed Summary

This randomized phase II/III trial studies how well giving maintenance chemotherapy with or without local consolidation therapy works in treating patients with stage IV non-small cell lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium, erlotinib hydrochloride, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Local consolidation therapy such as radiation/stereotactic body radiation or surgery may kill cancer cells left after initial treatment. Giving maintenance chemotherapy and local consolidation therapy together may work better than maintenance chemotherapy alone in treating patients with stage IV non-small cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Israel, Saudi Arabia, United States

Timeline

Phase 2Active
2017201820192020202120222023202420252026202720282029
First PostedMay 3, 2017
Enrollment StartApr 7, 2017
Primary CompletionDec 20, 2023
Study CompletionDec 1, 2028
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 9.2 years ago

Interventions

3-Dimensional Conformal Radiation Therapy (3D-CRT)radiation

Undergo 3DCRT

Docetaxeldrug

Given IV

Gemcitabinedrug

Given IV

Intensity-Modulated Radiation Therapy (IMRT)radiation

Undergo IMRT

Pemetrexed Disodiumdrug

Given IV

Stereotactic Body Radiation Therapy (SBRT)radiation

Undergo SBRT

Erlotinib Hydrochloridedrug

Given PO

Pembrolizumabdrug

Given IV